Relationship
Shionogi invests in ViiV Healthcare
Shionogi raised its economic interest in ViiV Healthcare from 10% to 21.7% by acquiring the cancelled Pfizer holding in 2026, and keeps a ViiV board seat; it discovered the integrase inhibitors dolutegravir and cabotegravir.
- From
- Shionogi
- Importance
- High
- Confidence
- 88/100
Sources (1)
- GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding — GSK, January 20, 2026
History
- 2026-11-05New link: Shionogi invests in ViiV Healthcare — new link (High).
Cite this
InsightNodes, "Shionogi invests in ViiV Healthcare" — High importance, 1 source. https://insightnodes.com/claims/r/shionogi~viiv-healthcare~invests-in (accessed November 10, 2026).
This page has a permanent address — link to it from notes, articles or models. Not investment advice.